hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro

SIMPLE SUMMARY: Although newer generations of androgen deprivation therapy such as enzalutamide are providing hope, it is clinically challenging to deliver effective therapy to individuals with metastatic castrate-resistant prostate cancer. Between 20–40% of patients have intrinsic resistance to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Marvin C. J., Baird, Anne-Marie, Greene, John, McNevin, Ciara, Ronan, Karine, Podlesniy, Petar, Sheils, Orla, Gray, Steven G., McDermott, Ray S., Finn, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715667/
https://www.ncbi.nlm.nih.gov/pubmed/34945002
http://dx.doi.org/10.3390/cancers13246383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715667/
https://www.ncbi.nlm.nih.gov/pubmed/34945002
http://dx.doi.org/10.3390/cancers13246383

Ejemplares similares